BlinkLab (ASX:BB1): Smartphone ADHD Diagnostics Clear European Study

BlinkLab (ASX:BB1): Smartphone ADHD Diagnostics Clear European Study — Commercialisation in Sight?

Sonal Goyal

09 September 2026 11:06 AM AEST

BlinkLab (ASX:BB1): Smartphone ADHD Diagnostics Clear European Study — Commercialisation in Sight?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

1. BlinkLab is developing smartphone-based digital diagnostics using artificial intelligence and Machine Learning for neurodevelopmental conditions.

2. Recent FY26 updates highlighted positive European ADHD study results, continued clinical development and a newly strengthened board.

3. Key catalyst: Publication of positive European ADHD study results in peer-reviewed journals strengthening the evidence base.

4. Primary risk: Clinical validation risk as the technology must demonstrate sufficient diagnostic accuracy and clinical Utility across multiple studies.

BlinkLab (ASX:BB1) is an Australian-listed healthcare technology company developing smartphone-based digital diagnostics for neurodevelopmental conditions including ADHD, autism spectrum disorder and related presentations. The company's platform uses a smartphone's camera and AI algorithms to measure subtle physiological responses, such as eye blink reflexes and other sensorimotor signals, that may serve as objective biomarkers for neurodevelopmental conditions. The current diagnostic process for conditions such as ADHD typically relies on subjective clinical assessment and behavioural questionnaires, creating an opportunity for objective, technology-based tools that could complement or enhance traditional diagnostic approaches. BlinkLab is building a clinical evidence base through studies across multiple international markets, positioning its technology within existing neurodevelopmental assessment workflows.

Latest Developments

BlinkLab is developing smartphone-based digital diagnostics using artificial intelligence and machine learning for neurodevelopmental conditions. Recent FY26 updates highlighted positive European ADHD study results, continued clinical development and a newly strengthened board. The company is progressing its technology toward broader validation and commercialisation, with clinical evidence and regulatory pathways remaining important milestones.

Key Risks to Watch

• Clinical validation risk as the technology must demonstrate sufficient diagnostic accuracy and clinical utility across multiple studies

• Regulatory pathway risk in obtaining medical device clearances across different jurisdictions

• Commercial adoption risk if clinicians or healthcare systems are slow to adopt digital diagnostic tools

• Funding risk given the Capital requirements of clinical development programs before Revenue materialises

• Competition from other digital biomarker and neurodevelopmental diagnostic companies pursuing similar opportunities

Key Catalysts to Watch

• Publication of positive European ADHD study results in peer-reviewed journals strengthening the evidence base

• Additional clinical trial results across other neurodevelopmental conditions supporting the platform's breadth

• Regulatory clearance submissions in key markets including the United States and Europe

• Commercial partnerships with clinical organisations, healthcare systems or diagnostic companies

• Board and Leadership enhancements improving strategic execution capability

Conclusion

BlinkLab (ASX:BB1) represents a healthcare sector opportunity on the ASX with a clearly defined strategic direction and a set of near-term catalysts that could influence performance over the coming reporting periods. Investors and market observers should monitor the key risks identified, including funding, execution and competitive dynamics, alongside the commercial milestones that could validate the company's growth thesis. As always, independent research, consideration of individual Risk tolerance and professional financial advice are recommended before making any Investment decisions. The company's upcoming reporting periods, contract announcements and operational updates will be the clearest indicators of near-term trajectory.

Disclaimer: This article is intended for informational and general news purposes only. It does not constitute financial advice. Always conduct your own research and consult a licensed financial adviser before making investment decisions.

FAQs

Q: What does BlinkLab do?

A: BlinkLab develops smartphone-based digital diagnostics using AI and machine learning to measure physiological signals that may serve as objective biomarkers for neurodevelopmental conditions such as ADHD and autism.

Q: What were the European ADHD study results?

A: BlinkLab reported positive results from a European ADHD study, providing clinical evidence that its smartphone-based measurement technology can detect physiological signals associated with ADHD presentations.

Q: How does BlinkLab's diagnostic technology work?

A: The technology uses a smartphone camera to capture and analyse subtle physiological responses including eye blink reflexes and sensorimotor signals, which are then processed by AI algorithms to generate diagnostic insights.

Q: What neurodevelopmental conditions does BlinkLab target?

A: BlinkLab's primary focus is ADHD, with the platform also being explored for autism spectrum disorder and other neurodevelopmental conditions where objective digital biomarkers could complement existing assessment methods.

Q: What regulatory pathways does BlinkLab need to pursue?

A: BlinkLab's diagnostic tools would need to obtain medical device regulatory clearances in target markets including the FDA in the United States and CE marking in Europe before commercial deployment.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.